Patents Issued in August 19, 2008
  • Patent number: 7413995
    Abstract: In one embodiment, a package-to-package stack is assembled comprising a first integrated circuit package, and a second integrated circuit package which are mechanically and electrically connected using an interposer. In one embodiment, the interposer 106 includes columnar interconnects which may be fabricated by etching a conductive member such as copper foil, for example. In one application, the pitch or center to center spacing of the columnar interconnects may be defined by masking techniques to provide an interconnect pitch suitable for a particular application. In yet another aspect, etching rates may be controlled to provide height to width aspect ratios of the columnar interconnects which are suitable for various applications.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: August 19, 2008
    Assignee: Intel Corporation
    Inventors: Terry L. Sterrett, Devendra Natekar
  • Patent number: 7413996
    Abstract: A method of forming a high k gate insulation layer in an integrated circuit on a substrate. A high k layer is deposited onto the substrate, and patterned with a mask to define the high k gate insulation layer and exposed portions of the high k layer. The exposed portions of the high k layer are subjected to an ion implanted species that causes lattice damage to the exposed portions of the high k layer. The lattice damaged exposed portions of the high k layer are etched to leave the high k gate insulation layer.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: August 19, 2008
    Assignee: LSI Corporation
    Inventors: Arvind Kamath, Wai Lo, Venkatesh Gopinath
  • Patent number: 7413997
    Abstract: In some embodiments, the inventive concept provides for a process for depositing a substance on a nanostructured surface, particularly for organic components, to yield a substantially consistent and homogeneous coating on the nanostructured surface. The substance to be applied is dissolved in a solvent. The coating for the nanostructured surface is then produced by depositing the first dissolved substance on the nanostructured surface.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: August 19, 2008
    Assignee: Konarka Technologies, Inc.
    Inventors: Christoph Brabec, Pavel Schilinsky, Christoph Waldauf
  • Patent number: 7413998
    Abstract: A biased pulse DC reactor for sputtering of oxide films is presented. The biased pulse DC reactor couples pulsed DC at a particular frequency to the target through a filter which filters out the effects of a bias power applied to the substrate, protecting the pulsed DC power supply. Films deposited utilizing the reactor have controllable material properties such as the index of refraction. Optical components such as waveguide amplifiers and multiplexers can be fabricated using processes performed on a reactor according to the present invention.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: August 19, 2008
    Assignee: SpringWorks, LLC
    Inventors: Hongmei Zhang, Mukundan Narasimhan, Ravi B. Mullapudi, Richard E. Demaray
  • Patent number: 7413999
    Abstract: A corner fitting and a method of forming a corner fitting including steps of providing a flat woven fabric including a first woven portion having first and second direction woven fibers, a second woven portion adjacent the first woven portion having first direction fibers and sacrificial second direction fibers and a third semi-woven portion having first direction fibers selectively engaged by the sacrificial second direction yarns. The method further comprising steps of folding the flat woven fabric in at least one direction, and removing the sacrificial second direction fibers, wherein during removal, the sacrificial second direction fibers are replaced in the second woven portion by the first direction fibers of the third semi-woven portion and form a corner fitting having continuous fibers connecting all sides.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 19, 2008
    Assignee: Albany Engineered Composites, Inc.
    Inventor: Jonathan Goering
  • Patent number: 7414000
    Abstract: A method for reducing the defect density of glass comprising melting a glass composition comprising from 65-75 wt. % of SiO2; from 10-20 wt. % of Na2O; from 5-15 wt. % of CaO; from 0-5 wt. % of MgO; from 0-5 wt. % of Al2O3; from 0-5 wt. % of K2O; from 0-2 wt. % Fe2O3; and from 0-2% FeO, wherein the glass composition has a total field strength index of greater than or equal to 1.23 is disclosed.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: August 19, 2008
    Assignee: PPG Industries Ohio, Inc.
    Inventors: Charlene S. Smith, George A. Pecoraro
  • Patent number: 7414001
    Abstract: Isopipes for use in making sheet glass by a fusion process are provided which exhibit reduced sag. The isopipes are composed of a zircon refractory which has a mean creep rate (MCR) at 1180° C. and 250 psi and a 95 percent confidence band (CB) for said mean creep rate such that the CB to MCR ratio is less than 0.5, the MCR and the CB both being determined using a power law model. The zircon refractory can contain titania (TiO2) at a concentration greater than 0.2 wt. % and less than 0.4 wt. %. A concentration of titania in this range causes the zircon refractory to exhibit a lower mean creep rate than zircon refractories previously used to make isopipes. In addition, the variation in mean creep rate is also reduced which reduces the chances that the zircon refractory of a particular isopipe will have an abnormally high creep rate and thus exhibit unacceptable sag prematurely.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: August 19, 2008
    Assignee: Corning Incorporated
    Inventors: John D. Helfinstine, Daniel J. Liebner, John L. Martin, Dean V. Neubauer, William R. Powell
  • Patent number: 7414002
    Abstract: The present invention provides an aluminum oxide-titanium nitride sintered body having good resistance to electrostatic damage and small variation in volume resistivity. The aluminum oxide-titanium nitride sintered body is mainly composed of 65 to 85% by weight of aluminum oxide and titanium nitride constituting the rest. The average of the sum of the crystal grain sizes of the aluminum oxide and the titanium nitride is 0.4 to 2.0 ?m. The aluminum oxide has a mean crystal grain size of 0.5 to 2.2 ?m and the titanium nitride has a mean crystal grain size of 0.2 to 1.6 ?m.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: August 19, 2008
    Assignee: Kyocera Corporation
    Inventors: Minoru Nakasuga, Kazuhide Kusano
  • Patent number: 7414004
    Abstract: The present invention provides a gas diffusion layer for a fuel cell which has proper rigidity, is easy to handle and contributes to the improvement of the productivity of fuel cells. A method for producing a gas diffusion layer for a fuel cell including a first step of: impregnating a conductive porous substrate made of a conductive carbon fiber cloth or conductive carbon fiber felt with a first dispersion containing a first fluorocarbon resin having thermoplasticity; and baking the first conductive porous substrate at a first baking temperature of not less than the melting point of the first fluorocarbon resin and less than the decomposition temperature of the first fluorocarbon resin to enhance the rigidity of the conductive porous substrate.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: August 19, 2008
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Akihiko Yoshida, Yoichiro Tsuji, Masaki Yamauchi, Yoshihiro Hori, Makoto Uchida, Hisaaki Gyoten, Teruhisa Kanbara
  • Patent number: 7414005
    Abstract: The present invention relates to a process for preparing a catalyst composition for olefin polymerization, which comprises preparing a catalyst solid in a first step by bringing A) at least one support, B) at least one organic compound having at least one functional group containing active hydrogen, C) at least one organometallic compound and D) at least one organic transition metal compound into contact with one another, then bringing this catalyst solid into contact with E) at least one organoaluminum compound in a second step and then using this mixture for the polymerization without further work-up. In addition, the invention relates to catalyst system for the polymerization of olefins which comprise such catalyst compositions, to the use of the catalyst compositions or the catalyst systems for the polymerization of olefins and to a process of the polymerization of olefins.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: August 19, 2008
    Assignee: Basell Polyolefine GmbH
    Inventor: Roland Kratzer
  • Patent number: 7414006
    Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a heteroaryl-amine compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 19, 2008
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: David H. McConville, Lily Ackerman, Robert T. Li, Xiaohong Bei, Matthew C. Kuchta, Tom Boussie, John F. Walzer, Jr., Gary Diamond, Francis C. Rix, Keith A. Hall, Anne LaPointe, James Longmire, Vince Murphy, Pu Sun, Dawn Verdugo, Susan Schofer, Eric Dias
  • Patent number: 7414007
    Abstract: A catalyst and process is disclosed to selectively upgrade a paraffinic feedstock to obtain an isoparaffin-rich product for blending into gasoline. The catalyst comprises a support of a tungstated oxide or hydroxide of a Group IVB (IUPAC 4) metal, a phosphorus component, and at least one platinum-group metal component which is preferably platinum. The catalyst has a structure other than a hetropoly anion structure.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: August 19, 2008
    Assignee: UOP LLC
    Inventors: Ralph D. Gillespie, Feng Xu
  • Patent number: 7414008
    Abstract: The present invention provides: a production process for a catalyst for synthesis of an unsaturated aldehyde and/or an unsaturated carboxylic acid, which production process is suitable for producing the catalyst with good reproducibility, wherein the catalyst is excellent in activity, selectivity, and physical strength; this catalyst; and a production process for the unsaturated aldehyde and/or the unsaturated carboxylic acid by using this catalyst.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 19, 2008
    Assignee: Nippon Sholonbai Co., Ltd.
    Inventor: Hiromi Yunoki
  • Patent number: 7414009
    Abstract: A method of producing composite particles of titanium dioxide and a compound inactive as a photocatalyst, comprising the steps of preparing a water based slurry of pH 3 to 5 comprising titanium dioxide, preparing a water based solution comprising a compound inactive as a photocatalyst, and reacting the slurry and the water based solution together at a pH within a range from 4 to 10 is provided, together with highly active photocatalyst particles produced using such a method, and potential uses of such photocatalyst particles.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: August 19, 2008
    Assignee: Showa Denko K.K.
    Inventors: Jun Tanaka, Masayuki Sanbayashi, Yoshinori Ueyoshi, Hagihara Hiroyuki
  • Patent number: 7414010
    Abstract: The invention encompasses a fabric book with high resolution sublimation printed images and a method of making such a fabric book. The fabric book of the invention has a plurality of fabric pages. The fabric pages are made of a synthetic material with an original softness corresponding to the synthetic material. At least one fabric page has a high resolution sublimation printed image imprinted using the method of the invention. The fabric page with the high resolution image substantially retains the original softness, even after printing. The preferred method of creating the high resolution images in the fabric books begins with selecting an appropriate original object. A digital rendition of the original object is created. The digital rendition is edited to create an edited image with optimum print resolution. A color separation is performed on the edited image to create a color separated image. Optimal sublimation inks are prepared and suitable sublimation paper is selected.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: August 19, 2008
    Assignee: Sandvik Innovations, LLC
    Inventor: Roger Burrows
  • Patent number: 7414011
    Abstract: Disclosed are compounds of the formula (I) or salts thereof in which R1, R2, R3, R4, I, R5, Q, R4, W, X, Y, V and Z, are as defined in the specification, which are suitable for use as herbicides or plant growth regulators. Also disclosed are processes for preparing the compounds of formula (I) or salts thereof.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: August 19, 2008
    Assignee: Hoechst Schering Agrevo GmbH
    Inventors: Hansjörg Dietrich, Christian Waldraff, Lothar Willms, Hermann Bieringer, Christopher Rosinger, Felix Thürwächter, Thomas Auler
  • Patent number: 7414012
    Abstract: A waterborne lubricant, useful in the plastic working of metals, which imparts a lubricating behavior to the surface of metals in the absence of a conversion coating contains (A) water-soluble inorganic salt and (B) wax, wherein these components are dissolved or dispersed in water and the (B)/(A) solids weight ratio is 0.3 to 1.5. The (C) metal salt of a fatty acid can also be present at a (C)/(A) solids weight ratio of 0.01 to 0.4. The water-soluble inorganic salt (A) can be selected from the sulfates, silicates, borates, molybdates, and tungstates. The wax (B) can be a synthetic wax having a melting point of 70 to 150° C. A lubricating coating is formed by application to give a post-drying add-on of 0.5 to 40 g/m2. A method for using said lubricant is also provided.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: August 19, 2008
    Assignee: Henkel KGaA
    Inventors: Yasuo Imai, Syuji Nagata, Masayuki Yoshida
  • Patent number: 7414013
    Abstract: Sulfurized olefin compositions and compounds of the formula: wherein R1 is hydrogen or methyl; X is sulfur or oxygen; m is an integer from 1 to 9; and n is 0 or 1, and when n is 0 then R1 is methyl, and when n is 1 then R1 is hydrogen are disclosed. The resulting compounds are particularly the polyisobutyl-1,2-dithiole-4-cyclopentene-3-thione compounds and derivatives are useful in lubricating oils.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: August 19, 2008
    Assignee: Chevron Oronite Company LLC
    Inventors: Kenneth D. Nelson, Frank Plavac
  • Patent number: 7414014
    Abstract: A method and system to reduce fuel consumption and environmental impact in a two-stroke engine. Fresh system oil having a TBN less than 10 is provided and used in the two-stroke engine to produce partially used system oil. The partially used system oil is withdrawn from the two stroke engine and at least one friction modifier is added to at least some of the withdrawn partially used system oil, wherein the addition of the at least one friction modifier reduces the friction coefficient of the withdrawn system oil, resulting in a system oil having reduced friction. The system oil with reduced friction is combined with partially used system oil remaining in said two-stroke and the combined system oil is used to lubricate pistons of said two-stroke engine.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: August 19, 2008
    Assignee: A.P. Moeller-Maersk/AS
    Inventors: Giuseppe Natoli, Giulio Giovanni Pometto, Alfio Bonciolini, Hans Heinrich Petersen, Jørn Dragsted, Claus Martin Olesen, Klaus-Werner Damm
  • Patent number: 7414015
    Abstract: A method for lubricating a metal workpiece during a metalworking process includes delivering supercritical carbon dioxide to the workpiece during the metalworking process. The supercritical carbon dioxide acts as a lubricant, coolant, chip evacuator, and/or carrier for another lubricant or corrosion inhibitor.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: August 19, 2008
    Assignee: The Regents of The University of Michigan
    Inventors: Steven J. Skerlos, Kim F. Hayes, Andres F. Clarens
  • Patent number: 7414016
    Abstract: A cleaning composition with a limited number of natural ingredients contains alkyl polyglucoside, a 2-hydroxycarboxylic acid, and a fragrance containing lemon oil or d-limonene. The cleaning composition optionally has a small amount of dye, colorant, and preservative. The cleaning composition can be used to clean hard surfaces and cleans as well or better than commercial compositions containing synthetically derived cleaning agents.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: August 19, 2008
    Assignee: The Clorox Company
    Inventors: Gregory van Buskirk, Aram Garabedian, Ryan K. Hood, Stephen Bradford Kong
  • Patent number: 7414017
    Abstract: Cleaning compositions containing C8-C10 alkylpolyglucosides, have low filming and streaking when combined with C2-C4 alcohols and propylene glycol ethers. The low filming and streaking occurs even in the presence of quaternary ammonium biocides.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: August 19, 2008
    Assignee: The Clorox Company
    Inventors: Stephen Bradford Kong, Sonia H. Burciaga, Andrew Kilkenny
  • Patent number: 7414018
    Abstract: A product for cleaning stains. In one embodiment, the product may include a piece of material and a volume of carbonated water, both sealed within a container. When a stain is encountered, the container may be opened and the piece of material that has been wetted by the carbonated water may be used to clean the stain.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: August 19, 2008
    Inventors: Richard M. Huff, Amy N. Huff
  • Patent number: 7414019
    Abstract: This invention features a method for treating a bone condition in a patient, e.g., a mammal, a human, a horse, a dog, or a cat. The method includes administering an effective amount of FGF-8, FGF-8 analog, or a FGF-8 agonist to the patient.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: August 19, 2008
    Assignee: Auckland Uniservices Limited
    Inventors: Jillian Cornish, Ian Reginald Reid, Jianming Lin
  • Patent number: 7414020
    Abstract: The invention provides for a novel human checkpoint kinase gene, hCDS1, comprising the nucleic acid sequence of residues 66-1694 of SEQ ID NO: 1, a protein expressed from the gene, fragments and functional equivalents of the protein. The invention also provides for pharmaceutical compositions comprising a hCDS1 protein, and methods utilizing the protein.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: August 19, 2008
    Assignee: The Scripps Research Institute
    Inventors: Walter H. M. L. Luyten, Andrew E. Parker, Clare McGowan, Alessandra Blasina
  • Patent number: 7414021
    Abstract: A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.
    Type: Grant
    Filed: October 1, 2005
    Date of Patent: August 19, 2008
    Inventor: Vincent Carmine Giampapa
  • Patent number: 7414022
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: August 19, 2008
    Assignee: Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Patent number: 7414023
    Abstract: The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these peptides, to diagnostic and pharmaceutical compositions comprising these peptides, to the use of these peptides for pharmaceutical and research preparations, to methods using these peptides in diagnostic assays for determination of the concentrations of various molecular forms of PSA, to methods for modulating the PSA enzyme activity and PSA activity dependent conditions by using these peptides either in vivo or in vitro and to the use of these peptides in procedures for biochemical isolation and purification of PSA.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: August 19, 2008
    Assignee: Licentia Ltd.
    Inventors: Stenman Ulf-Hakan, Erkki Koivunen, Jari Leinonen, Ale Närvänen
  • Patent number: 7414024
    Abstract: The subject of the present invention concerns proteins with IL-6 inhibiting activity and thier use, and the use of proteins containing at least the amino acid seqeunce SEQ ID NO. 4 as medicianl product, in paritcular as anti-cancerous agent.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: August 19, 2008
    Assignees: Universite Claude Bernard Lyon 1, Centre Leon Berard, Institut National de la Sante et de la Recherche Medicale - I.N.S.E.R.M., Hospices Civils de Lyon
    Inventors: Jean-Yves Blay, Laurent Alberti
  • Patent number: 7414025
    Abstract: The invention relates to a non-cleavable, plastidial targeting polypeptide derived from a protein from the inner membrane of plant chloroplasts. Said peptide is particularly suitable for importing proteins of interest in plasts.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: August 19, 2008
    Assignee: Genoplante-Valor
    Inventors: Stéphane Miras, Daniel Salvi, Norbert Rolland, Jacques Joyard, Myriam Ferro, Jérome Garin, Didier Grunwald
  • Patent number: 7414026
    Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-?B) activating pathway useful in the treatment of NF-?B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I?B.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: August 19, 2008
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
  • Patent number: 7414027
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: August 19, 2008
    Assignee: Childen's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker
  • Patent number: 7414028
    Abstract: The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: August 19, 2008
    Assignee: BioSurFace Engineering Technologies, Inc.
    Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
  • Patent number: 7414029
    Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A-RnYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: August 19, 2008
    Assignee: Theratechnologies, Inc.
    Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran, Annie Bergeron
  • Patent number: 7414030
    Abstract: The present invention discloses compounds of formulaes I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: August 19, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Nha Huu Vo, Guoqiang Wang, Guoyou Xu, Ying Hou, Ying Sun, Ly Tam Phan, Zhe Wang, Yat Sun Or
  • Patent number: 7414031
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: August 19, 2008
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jesse D. Keicher, Christopher D. Roberts, Natalia B. Dyatkina
  • Patent number: 7414032
    Abstract: The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+ helper T cells and CD8+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+ helper T cells is a molecule identified by the SEREX method and that recognized by CD8+ cytotoxic T cells is a tumor-specific antigen, tumor-associated antigen or cell-associated antigen. Furthermore, so that the antigens recognized by CD4+ helper T cells and CD8+ CTL are expressed and presented on the same cell, the expression vectors preferably are immobilized on the same gold particle and administered into the cell by gene gun; however, this invention is not restricted thereto. The vaccine can also be used as a pharmaceutical agent.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: August 19, 2008
    Assignee: Immunofrontier, Inc.
    Inventor: Hiroshi Shiku
  • Patent number: 7414033
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 1, such as obesity and obesity-related conditions, are provided.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: August 19, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Mark J. Graham
  • Patent number: 7414034
    Abstract: The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brain. Antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of glutamic acid decarboxylase (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the thalamic motor nuclei for the downregulation of GABA receptors.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: August 19, 2008
    Assignee: Thomas Jefferson University
    Inventor: Jay S. Schneider
  • Patent number: 7414035
    Abstract: Disclosed herein are novel composition and methods for altering the proliferation of a cell. Included are wild-type and mutant hKIS polypeptides along with cyclin kinase inhibitors containing mutations that prevent their inhibition with serine/threonine kinases.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: August 19, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: Gary J Nabel, Elizabeth G. Nabel, Manfred Boehm
  • Patent number: 7414036
    Abstract: Adenosine analogue-type A3 receptor agonists having the formula wherein D is N or CH; E is O; X1 is a group of the formula —CR20R2 1-CYCLE, where R20 and R21 are the same or different and are H, F or CH3; CYCLE is where G is N, CH, CF, CCH3 or CCF3, M is H, Y is —O— or N?, and Z is —N? when Y is O, or is O when Y is —N?; R5 is H, CH3, I, Br, Cl, CF3, OH or NH2; and R8 is —NR9R10, —CHR9R10 or —N?CR9R10, where R9 and R10 are the same and are C1-C4 alkyl, C1-C4 alkenyl or C1-C4 alkoxyalkyl X2 is mono-N— or di-N,N—(C1-C4)alkylaminocarbonyl, mono-N—or di-N,N—(C3-C5)cycloalkyl-aminocarbonyl or N-(C1-C4)alkyl-N-(C3-C5)cycloalkylamino-carbonyl; X3 is OH or NH2; X4 is OH; X5 is H , halogen, (C1-C10)alkyl , (C2-C10)alkenyl , (C2-C10)alkynyl , or either of the latter two groups where terminally substituted by an aryl or heteroaryl group and, when having a terminal methyl group, optionally further terminally substituted by hydroxyl.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: August 19, 2008
    Assignee: Muscagen Limited
    Inventors: Luis Garcia Sevillano, Christopher McGuigan, Robin Havard Davies
  • Patent number: 7414037
    Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: August 19, 2008
    Assignee: The Regents of the University of California
    Inventors: Alan Verkman, Nitin Dattatraya Sonawane, Chatchai Muanprasat
  • Patent number: 7414038
    Abstract: The object of the present invention is to provide an embolizing material which is easily handleable and stable in quality and is solved by providing an embolizing material comprising an ester derivative of a polysaccharide having a weight-average molecular weight of 10,000-500,000 daltons and an average substitution degree of acyl group of over two; an embolizing agent for arteriovenous aneurysm, which comprises the embolizing material and an appropriate physiologically acceptable water-soluble organic acid; and a method of producing an embolizing agent, which comprises a step of dissolving the embolizing material in an appropriate physiologically acceptable water-soluble organic solvent.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 19, 2008
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Kazushi Kinugasa, Shinya Mandai
  • Patent number: 7414039
    Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: August 19, 2008
    Assignee: The Regents of the University of California
    Inventor: C. Lowell Parsons
  • Patent number: 7414040
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: August 19, 2008
    Assignee: SmithKline Beecham Corporation
    Inventor: Dirk A. Heerding
  • Patent number: 7414041
    Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: August 19, 2008
    Assignee: Trustees Of Tufts College
    Inventor: Stuart B. Levy
  • Patent number: 7414042
    Abstract: Compositions and methods are disclosed for treating melanoma wherein a betulinic acid derivative is the active compound in the composition to be administered. The compositions are optionally applied topically is inserted therefor.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: August 19, 2008
    Assignee: The Board of Trustees of The University of Illinois
    Inventors: John M. Pezzuto, Tapas K. DasGupta, Darrick S. H. L. Kim
  • Patent number: 7414043
    Abstract: This invention describes the new 9?-substituted estratrienes of general formula I in which R3, R7, R7?, R13, R16 as well as R17 and R17? have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: August 19, 2008
    Assignee: Schering AG
    Inventors: Dirk Kosemund, Gerd Mueller, Alexander Hillisch, Karl-Heinrich Fritzemeier, Peter Muhn
  • Patent number: 7414044
    Abstract: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with diabetes and obesity.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: August 19, 2008
    Inventor: Robert F. Hofmann
  • Patent number: 7414045
    Abstract: Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: August 19, 2008
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Benedetta Crescenzi, Olaf Kinzel, Ester Muraglia, Federica Orvieto, Giovanna Pescatore, Michael Rowley, Vincenzo Summa